- ISIN
- US89532M1018
- CUSIP
- 89532M101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 7, 2019
Highlights
- Market Cap
- $2.59B
- Enterprise Value
- $2.57B
- EPS (TTM)
- -$0.47
- Gross Profit (TTM)
- -$31.00K
- EBITDA (TTM)
- -$49.16M
- Year Range
- $6.55 - $20.22
- Target Price
- $19.25
- ROA (TTM)
- -25.40%
- ROE (TTM)
- -26.50%
- Avg. Volume (1M)
- 3M
- Avg. Volume Value (1M)
- $46.29M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TRVI Performance Chart
Trevi Therapeutics, Inc. (TRVI) is up 45.8% since the beginning of the year. At $18 per share, TRVI is trading 9.7% below its 52-week high of $20. Investors who bought $1,000 worth of TRVI shares 5 years ago would now be looking at an investment worth $9,606.
Loading charts...
Compare this symbol against anything
Returns By Period
Trevi Therapeutics, Inc. (TRVI) has returned 45.77% so far this year and 148.98% over the past 12 months.
Trevi Therapeutics, Inc.
- 1D
- -0.82%
- 1M
- 1.78%
- 6M
- 74.31%
- YTD
- 45.77%
- 1Y
- 148.98%
- 3Y*
- 94.77%
- 5Y*
- 57.22%
- 10Y*
- —
- ALL TIME*
- 9.45%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
TRVI Monthly Returns History
Based on dividend-adjusted daily data since May 7, 2019, TRVI's average daily return is +0.21%, while the average monthly return is +5.21%. At this rate, an investment would double in approximately 1.1 years.
Historically, 47% of months were positive and 53% were negative. The best month was Mar 2022 with a return of +243.8%, while the worst month was Sep 2022 at -51.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.
On a daily basis, TRVI closed higher 47% of trading days. The best single day was Mar 31, 2020 with a return of +92.4%, while the worst single day was Mar 30, 2020 at -25.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.37% | 13.85% | 0.08% | 15.34% | 2.76% | 31.90% | -2.14% | 45.77% | |||||
| 2025 | -4.37% | 14.72% | 39.16% | 9.86% | -5.79% | -15.98% | 35.37% | -2.03% | 26.12% | 27.43% | 13.12% | -5.08% | 203.88% |
| 2024 | 5.97% | 105.63% | 18.15% | -15.07% | -12.29% | 15.95% | 6.71% | -0.63% | 5.70% | -11.83% | -2.21% | 43.06% | 207.46% |
| 2023 | 20.73% | 2.58% | -22.59% | 85.95% | -37.21% | 10.65% | -0.42% | -7.14% | -1.36% | -18.35% | -36.80% | 19.11% | -30.57% |
| 2022 | -18.47% | 0.36% | 243.75% | 22.73% | -10.37% | 16.12% | 8.90% | 3.92% | -51.57% | 28.57% | -5.05% | 2.66% | 146.74% |
| 2021 | 23.14% | -5.37% | -3.90% | -15.50% | -6.99% | 5.63% | -15.56% | -12.63% | -15.66% | -16.07% | -15.35% | -21.36% | -67.68% |
Benchmark Metrics
Trevi Therapeutics, Inc. has an annualized alpha of 62.69%, beta of 0.36, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since May 07, 2019.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (43.52%) than losses (39.89%) - typical of diversified or defensive assets.
- Beta of 0.36 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 62.69%
- Beta
- 0.36
- R²
- 0.01
- Upside Capture
- 43.52%
- Downside Capture
- 39.89%
Return for Risk
Risk / Return Rank
TRVI ranks 92 for risk / return — above 92% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Trevi Therapeutics, Inc. (TRVI) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TRVI | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.91 | ||
| Sortino ratioReturn per unit of downside risk | +0.75 | ||
| Omega ratioGain probability vs. loss probability | 1.36 | 1.25 | +0.10 |
| Calmar ratioReturn relative to maximum drawdown | 4.99 | 2.00 | +2.99 |
| Martin ratioReturn relative to average drawdown | 11.73 | 8.49 | +3.24 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Trevi Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Trevi Therapeutics, Inc. was 95.45%, occurring on Feb 23, 2022. Recovery took 913 trading sessions.
The current Trevi Therapeutics, Inc. drawdown is 6.41%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-95.45%Feb 2022 | 2y 8mo | 3y 7mo | 6y 4moJun 2019 - Oct 2025 | Bear market2022 |
-29.50%Jan 2026 | 1mo 13d | 2mo 22d | 4mo 5dDec 2025 - Apr 2026 | — |
-16.95%May 2019 | 1d | 24d | 24dMay 2019 - May 2019 | — |
-15.28%Jul 2026 | 5d | — | 25dJul 2026 - now | — |
-14.03%May 2026 | 28d | 29d | 1mo 27dApr 2026 - Jun 2026 | — |
Drawdown Indicators
| TRVI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.45% | -56.78% | -38.67% |
Max Drawdown (1Y)Largest decline over 1 year | -29.50% | -9.10% | -20.40% |
Max Drawdown (3Y)Largest decline over 3 years | -55.99% | -18.90% | -37.09% |
Max Drawdown (5Y)Largest decline over 5 years | -78.10% | -25.43% | -52.67% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -6.41% | -1.58% | -4.83% |
Average DrawdownAverage peak-to-trough decline | -60.47% | -10.70% | -49.77% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.53% | 2.14% | +10.39% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Trevi Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Trevi Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TRVI
Add Trevi Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TRVI